The UK now has access to a total of 357 million doses of vaccines from 7 different developers.
The government has today (Sunday 29 November) signed a deal for a further 2 million doses of Moderna’s promising vaccine candidate, bringing the total to 7 million doses for the UK.
Following today’s deal, the UK now has access to enough doses of Moderna’s vaccine candidate for around 3.5 million people.
To be approved for use in the UK, the Moderna vaccine must meet the strict standards of safety and effectiveness of the independent medicines regulator, the Medicines and Healthcare products Regulatory Agency (MHRA). If it is approved, 7 million doses could start to be delivered to the UK as early as spring 2021 – the same timetable as other countries in Europe.
The latest agreement is part of the government’s strategy to develop a diverse portfolio of promising vaccine candidates. The government has now secured 357 million vaccine doses from 7 different developers, giving the UK the best possible chance of protecting the public from coronavirus as soon as possible.
Business Secretary Alok Sharma said:
On 16 November, Moderna published initial data showing that its candidate is nearly 95% effective in protecting against COVID-19, with no safety issues identified to date. The safety data is still to be released by Moderna to show whether the vaccine is both safe and effective. Moderna is currently conducting phase 3 clinical trials of its vaccine and is using mRNA vaccine technology.
Until all the necessary stages are completed and a vaccine has been approved for use by the medicine regulator, the MHRA, the public must continue to take necessary actions to keep themselves and their loved ones safe, including following the Hands, Face, Space guidance and other public health advice in line with the area they live in.
Health and Social Care Secretary Matt Hancock said:
Chair of the government’s Vaccine Taskforce Kate Bingham said:
Today’s deal follows the independent regulator’s confirmation this week that it has received the necessary data of the Pfizer/BioNTech vaccine to progress their review into whether the vaccine meets the required standards. Encouraging results from the phase III trials of the Oxford University/AstraZeneca were also published this week.